The European type 2 diabetes market is contending with the convergence of innovative pharmaceutical offerings, such as Johnson & Johnson’s Invokana, AstraZeneca’s Xigduo, and Takeda’s Vipidia…
The fledgling biosimilars industry is full of uncertainties and nuances that differ by country, therapeutic specialty, and molecule. Securing a positive return on lengthy biosimilar development…
Outline • Sandoz's biosimilar filgrastim development program • Zarzio's European performance • U.S. oncologists' expected uptake of biosimilar filgrastim • U.S…
TreatmentTrends: Dry/Wet Age-Related Macular Degeneration (US) is an annual syndicated report series that offers a snapshot of dry and wet age-related macular degeneration (AMD) market dynamics and…
Gastrointestinal stromal tumors (GISTs) are rare cancers that belong to a group of cancers known as soft tissue sarcomas, which develop in supporting and connective tissues. GISTs account for…
Payers will be instrumental in determining the future commercial opportunity for biosimilars in the United States and across Europe. We conducted primary market research with surveyed MCO pharmacy…
This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the…
The launch of novel oral anticoagulants (NOACs), such as Bayer/Janssen’s Xarelto, Bristol-Myers Squibb/Pfizer’s Eliquis/Elicuis, and Boehringer Ingelheim’s Pradaxa/Pradaxar, in Brazil and…
Despite the comparatively low incidence of chronic myeloid leukemia (CML) in the United States, patient management requires extended durations of therapy, which in turn translates into a…
The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-Myers Squibb’s Yervoy) in 2010 and 2011, respectively, represented the first notable immunotherapy approvals in…
The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based…
Tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myelogenous leukemia (CML) over the last decade. However, as 2013-approved second-generation TKIs Bosulif (Pfizer’s…
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the seventh most common type of cancer worldwide and the second most common cause of cancer death worldwide. Most risk…
The hospital-treated methicillin-resistant Staphylococcus aureus (MRSA) infection market is dominated by generic vancomycin because of its low cost, physician familiarity and relatively high…
This report provides detailed analysis of the current and projected mar-kets for diabetic retinopathy (DR) and diabetic macular edema (DME). The DR population represents more than 5.8 million…